Peripheral profiling analysis for bipolar disorder reveals markers associated with reduced cell survival

Proteomics

Volumn 11, Issue 1, 2011, Pages 94-105

  Herberth, Marlis ^a   Koethe, Dagmar ^b   Levin, Yishai ^a   Schwarz, Emanuel ^a   Krzyszton, Natalia D ^a   Schoeffmann, Stephanie ^a   Ruh, Hermelindis ^a   Rahmoune, Hassan ^a   Kranaster, Laura ^b,c   Schoenborn, Torsten ^b   Leweke, Markus F ^b,c   Guest, Paul C ^a   Bahn, Sabine ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b UNIVERSITY OF COLOGNE   (Germany)

^c CENTRAL INSTITUTE OF MENTAL HEALTH   (Germany)

Author keywords

Biomarker; Cell death; Cytoskeleton; Inflammation; PBMC; Technology

Indexed keywords

ADULT; AMINO ACID SEQUENCE; ARTICLE; BIPOLAR DISORDER; CELL DEATH; CELL FUNCTION; CELL SURVIVAL; CONTROLLED STUDY; CYTOSKELETON; FEMALE; HUMAN; HUMAN CELL; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEOMICS;

ADULT; BIOLOGICAL MARKERS; BIPOLAR DISORDER; CELL SURVIVAL; CELLS, CULTURED; CHROMATOGRAPHY, LIQUID; FEMALE; HUMANS; IMMUNOBLOTTING; LEUKOCYTES, MONONUCLEAR; MALE; MASS SPECTROMETRY; YOUNG ADULT;

EID: 78650446303     PISSN: 16159853     EISSN: 16159861     Source Type: Journal    
DOI: 10.1002/pmic.201000291     Document Type: Article

References (53)

1. Smoller, J. W., Finn, C. T., Family, twin, and adoption studies of bipolar disorder. Am. J. Med. Genet. C Semin. Med. Genet. 2003, 123C, 48-58.
2. Ellicott, A., Hammen, C., Gitlin, M., Brown, G. et al., Life events and the course of bipolar disorder. Am. J. Psychiatry 1990, 147, 1194-1198.
3. Chuang, D. M., The antiapoptotic actions of mood stabilizers: molecular mechanisms and therapeutic potentials. Ann. N Y Acad. Sci. 2005, 1053, 195-204.
4. Marmol, F., Lithium: bipolar disorder and neurodegenerative diseases possible cellular mechanisms of the therapeutic effects of lithium. Prog. Neuro-psychopharmacol. Biol. Psychiatry 2008, 32, 1761-1771.
5. Wingo, A. P., Harvey, P. D., Baldessarini, R. J., Neurocognitive impairment in bipolar disorder patients: functional implications. Bipolar Disord. 2009, 11, 113-125.
6. Berk, M., Hallam, K., Lucas, N., Hasty, M. et al., Early intervention in bipolar disorders: opportunities and pitfalls. Med. J. Aust. 2007, 187, S11-S14.
7. Harris, L., Swatton, J., Wengenroth, M., Wayland, M. et al., Differences in protein profiles in schizophrenia prefrontal cortex compared to other major brain disorders. Clin. Schizophr. Relat. Psychoses 2007, 1, 73-91.
8. Johnston-Wilson, N. L., Sims, C. D., Hofmann, J. P., Anderson, L. et al., Disease-specific alterations in frontal cortex brain proteins in schizophrenia, bipolar disorder, and major depressive disorder. The Stanley Neuropathology Consortium. Mol. Psychiatry 2000, 5, 142-149.
9. Behan, A. T., Byrne, C., Dunn, M. J., Cagney, G. et al., Proteomic analysis of membrane microdomain-associated proteins in the dorsolateral prefrontal cortex in schizophrenia and bipolar disorder reveals alterations in LAMP, STXBP1 and BASP1 protein expression. Mol. Psychiatry 2009, 14, 601-613.
10. Kim, S., Webster, M. J., Correlation analysis between genome-wide expression profiles and cytoarchitectural abnormalities in the prefrontal cortex of psychiatric disorders. Mol. Psychiatry 2010, 15, 326-336.
11. Le-Niculescu, H., Kurian, S. M., Yehyawi, N., Dike, C. et al., Identifying blood biomarkers for mood disorders using convergent functional genomics. Mol. Psychiatry 2008, 14, 156-174.
12. Schwarz, E., Prabakaran, S., Whitfield, P., Major, H. et al., High throughput lipidomic profiling of schizophrenia and bipolar disorder brain tissue reveals alterations of free fatty acids, phosphatidylcholines, and ceramides. J. Proteome Res. 2008, 7, 4266-4277.
13. Montgomery, S. A., Asberg, M., A new depression scale designed to be sensitive to change. Br. J. Psychiatry 1979, 134, 382-389.
14. Hamilton, M., A rating scale for depression. J. Neurol. Neurosurg. Psychiatry 1960, 23, 56-62.
15. Young, R. C., Biggs, J. T., Ziegler, V. E., Meyer, D. A., A rating scale for mania: reliability, validity and sensitivity. Br. J. Psychiatry 1978, 133, 429-435.
16. Levin, Y., Schwarz, E., Wang, L., Leweke, F. M., Bahn, S., Label-free LC-MS/MS quantitative proteomics for large-scale biomarker discovery in complex samples. J. Sep. Sci. 2007, 30, 2198-2203.
17. Li, G. Z., Vissers, J. P., Silva, J. C., Golick, D. et al., Database searching and accounting of multiplexed precursor and product ion spectra from the data independent analysis of simple and complex peptide mixtures. Proteomics 2009, 9, 1696-1719.
18. Levin, Y., Wang, L., Schwarz, E., Koethe, D. et al., Global proteomic profiling reveals altered proteomic signature in schizophrenia serum. Mol. Psychiatry 2010, 15, 1088-1100.
19. Levin, Y., Wang, L., Ingudomnukul, E., Schwarz, E. et al., Real-time evaluation of experimental variation in large-scale LC-MS/MS-based quantitative proteomics of complex samples. J. Chromatogr. B Anal. Technol. Biomed. Life Sci. 2009, 877, 1299-1305.
20. Rothman, K. J., No adjustments are needed for multiple comparisons. Epidemiology 1990, 1, 43-46.
21. Benjamini, Y., Hochberg, Y., Controlling the false discovery rate: a practical and powerful approach to multiple testing. J. Roy. Stat. Soc. 1995, 30, 2190-2197.
22. Liu, X.-Y., Yang, J.-L., Chen, L.-J., Zhang, Y. et al., Comparative proteomics and correlated signaling network of rat hippocampus in the pilocarpine model of temporal lobe epilepsy. Proteomics 2008, 8, 582-603.
23. Bertenshaw, G. P., Yip, P., Seshaiah, P., Zhao, J. et al., Multianalyte profiling of serum antigens and autoimmune and infectious disease molecules to identify biomarkers dysregulated in epithelial ovarian cancer. Cancer Epidemiol. Biomarkers Prev. 2008, 17, 2872-2881.
24. Belardelli, F., Role of interferons and other cytokines in the regulation of the immune response. APMIS 1995, 103, 161-179.
25. Chen, J. J., Sun, Y., Nabel, G. J., Regulation of the proinflammatory effects of Fas ligand (CD95L). Science 1998, 282, 1714-1717.
26. Jüttner, S., Bernhagen, J., Metz, C. N., Röllinghoff, M. et al., Migration inhibitory factor induces killing of Leishmania major by macrophages: dependence on reactive nitrogen intermediates and endogenous TNF-alpha. J. Immunol. 1998, 161, 2383-2390.
27. Hedrick, J. A., Helms, A., Vicari, A., Zlotnik, A., Characterization of a novel CC chemokine, HCC-4, whose expression is increased by interleukin-10. Blood 1998, 91, 4242-4247.
28. Kuroiwa, T., Lee, E. G., Danning, C. L., Illei, G. G. et al., CD40 ligand-activated human monocytes amplify glomerular inflammatory responses through soluble and cell-to-cell contact-dependent mechanisms. J. Immunol. 1999, 163, 2168-2175.
29. O'Laughlin-Bunner, B., Radosevic, N., Taylor, M. L., Shivakrupa, D. C. et al., Lyn is required for normal stem cell factor-induced proliferation and chemotaxis of primary hematopoietic cells. Blood 2001, 98, 343-350.
30. Maier, W., Zobel, A., Wagner, M., Schizophrenia and bipolar disorder: differences and overlaps. Curr. Opin. Psychiatry 2006, 19, 165-170 110.1097/1001.yco.0000214342.0000252249.0000214382.
31. do Nascimento, C. A. M., Nogueira, C. W., Borges, V. C., Rocha, J. B. T., Changes in [3H]-glutamate uptake into platelets from patients with bipolar I disorder. Psychiatry Res. 2006, 141, 343-347.
32. Karege, F., Schwald, M., Papadimitriou, P., Lachausse, C., Cissé, M., The cAMP-dependent protein kinase A and brain-derived neurotrophic factor expression in lymphoblast cells of bipolar affective disorder. J. Affect. Disord. 2004, 79, 187-192.
33. Ortiz-Dominguez, A., Hernandez, M. E., Berlanga, C., Gutierrez-Mora, D. et al. Immune variations in bipolar disorder: phasic differences. Bipolar Disord. 2007, 9, 596-602.
34. Robinson, L. J., Ferrier, I. N., Evolution of cognitive impairment in bipolar disorder: a systematic review of cross-sectional evidence. Bipolar Disord. 2006, 8, 103-116.
35. Politi, P., Brondino, N., Emanuele, E., Increased proapoptotic serum activity in patients with chronic mood disorders. Arch. Med. Res. 2008, 39, 242-245.
36. Benes, F. M., Matzilevich, D., Burke, R. E., Walsh, J., The expression of proapoptosis genes is increased in bipolar disorder, but not in schizophrenia. Mol. Psychiatry 2006, 11, 241-251.
37. McIntyre, R. S., Soczynska, J. K., Konarski, J. Z., Woldeyohannes, H. O. et al., Should depressive syndromes be reclassified as metabolic syndrome type II? Ann. Clin. Psychiatry 2007, 19, 257-264.
38. Stolp, H. B., Dziegielewska, K. M., Review: Role of developmental inflammation and blood-brain barrier dysfunction in neurodevelopmental and neurodegenerative diseases. Neuropathol. Appl. Neurobiol. 2009, 35, 132-146.
39. Thomas, A. J., Davis, S., Ferrier, I. N., Kalaria, R. N. et al., Elevation of cell adhesion molecule immunoreactivity in the anterior cingulate cortex in bipolar disorder. Biol. Psychiatry 2004, 55, 652-655.
40. Kim, Y.-K., Jung, H.-G., Myint, A.-M., Kim, H. et al., Imbalance between pro-inflammatory and anti-inflammatory cytokines in bipolar disorder. J. Affect. Disord. 2007, 104, 91-95.
41. Padmos, R. C., Hillegers, M. H., Knijff, E. M., Vonk, R. et al., A discriminating messenger RNA signature for bipolar disorder formed by an aberrant expression of inflammatory genes in monocytes. Arch. Gen. Psychiatry 2008, 65, 395-407.
42. Chrousos, G. P., The hypothalamic-pituitary-adrenal axis and immune-mediated inflammation. N. Engl. J. Med. 1995, 332, 1351-1363.
43. Kenna, H. A., Jiang, B., Rasgon, N. L., Reproductive and metabolic abnormalities associated with bipolar disorder and its treatment. Harv. Rev. Psychiatry 2009, 17, 138-146.
44. Daban, C., Vieta, E., Mackin, P., Young, A. H., Hypothalamic-pituitary-adrenal axis and bipolar disorder. Psychiatr. Clin. North Am. 2005, 28, 469-480.
45. Tena-Sempere, M., Huhtaniemi, I., Sex in the brain - how the brain regulates reproductive function. Biochem. 2009, 31, 4-7.
46. Kenna, H. A., Jiang, B., Rasgon, N. L., Reproductive and metabolic abnormalities associated with bipolar disorder and its treatment. Harv. Rev. Psychiatry 2009, 17, 138-146.
47. Hermans, E. J., Putman, P., van Honk, J., Testosterone administration reduces empathetic behavior: a facial mimicry study. Psychoneuroendocrinology 2006, 31, 859-866.
48. Shamay-Tsoory, S., Harari, H., Szepsenwol, O., Levkovitz, Y., Neuropsychological evidence of impaired cognitive empathy in euthymic bipolar disorder. J. Neuropsychiatry Clin. Neurosci. 2009, 21, 59-67.
49. Tanriverdi, F., Silveira, L. F., MacColl, G. S., Bouloux, P. M., The hypothalamic-pituitary-gonadal axis: immune function and autoimmunity. J. Endocrinol. 2003, 176, 293-304.
50. Cutolo, M., Capellino, S., Montagna, P., Ghiorzo, P. et al., Sex hormone modulation of cell growth and apoptosis of the human monocytic/macrophage cell line. Arthritis Res. Ther. 2005, 7, R1124-1132.
51. Rybakowski, J. K., Antiviral and immunomodulatory effect of lithium. Pharmacopsychiatry 2000, 33, 159-164.
52. Kusalic, M., Engelsmann, F., Effect of lithium maintenance treatment on hypothalamic pituitary gonadal axis in bipolar men. J. Psychiatry Neurosci. 1996, 21, 181-186.
53. Aubry, J.-M., Schwald, M., Ballmann, E., Karege, F., Early effects of mood stabilizers on the Akt/GSK-3β signaling pathway and on cell survival and proliferation. Psychopharmacology 2009, 205, 419-429.